
US Special 301 Report should not target countries using compulsory licensing for access to medicines
MSF sent a letter to the new United States Trade Representative requesting that the Special 301 Report, starting from the 2021 edition and onward, does not penalize countries for using public health safeguards in their national laws or flexibilities contained in the TRIPS Agreement. Countries should be able to facilitate production, supply and access to protective equipment, treatments, vaccines or other medical technologies without undue pressure.